{"filing":{"accession_number":"0001213900-26-078138","cik":"0001871321","ticker":"DRTSW","company_name":"Alpha Tau Medical Ltd.","form":"6-K","filing_date":"2026-07-15","report_date":null,"primary_document":"ea0297988-6k_alpha.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1871321/000121390026078138/ea0297988-6k_alpha.htm"},"events":[{"id":18028,"run_id":16183,"accession_number":"0001213900-26-078138","anchor_item_number":"EX-99.1","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.75,"summary":"This press release announces a clinical trial milestone: successful treatment of the first patient in the ADMIRE study, a company-sponsored clinical trial evaluating Alpha DaRT for immunocompromised patients with recurrent cutaneous squamous cell carcinoma. The disclosure highlights the expansion of Alpha Tau's clinical program into a new patient population (immunocompromised patients) and represents progress toward potential regulatory approval and commercialization of its core therapeutic technology. While not a discrete M\u0026A, financing, or governance event, this clinical milestone is material to investors assessing the company's pipeline development and commercial prospects, particularly given Alpha Tau's dependence on Alpha DaRT success and the company's limited operating history.","company_name":"Alpha Tau Medical Ltd.","ticker":"DRTSW","filing_date":"2026-07-15","form":"6-K","submitted_at":null,"items":[{"id":16721,"accession_number":"0001213900-26-078138","item_number":"EX-99.1","item_title":"ea029798801ex99-1.htm","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.75,"reasoning":"This press release announces a clinical trial milestone: successful treatment of the first patient in the ADMIRE study, a company-sponsored clinical trial evaluating Alpha DaRT for immunocompromised patients with recurrent cutaneous squamous cell carcinoma. The disclosure highlights the expansion of Alpha Tau's clinical program into a new patient population (immunocompromised patients) and represents progress toward potential regulatory approval and commercialization of its core therapeutic technology. While not a discrete M\u0026A, financing, or governance event, this clinical milestone is material to investors assessing the company's pipeline development and commercial prospects, particularly given Alpha Tau's dependence on Alpha DaRT success and the company's limited operating history.","classifier_version":"claude-haiku-4-5-20251001+prompt-6be895f9","taxonomy_version":"v1.3","classified_at":"2026-07-15T12:31:37.955871+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":16721,"accession_number":"0001213900-26-078138","item_number":"EX-99.1","item_title":"ea029798801ex99-1.htm","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.75,"reasoning":"This press release announces a clinical trial milestone: successful treatment of the first patient in the ADMIRE study, a company-sponsored clinical trial evaluating Alpha DaRT for immunocompromised patients with recurrent cutaneous squamous cell carcinoma. The disclosure highlights the expansion of Alpha Tau's clinical program into a new patient population (immunocompromised patients) and represents progress toward potential regulatory approval and commercialization of its core therapeutic technology. While not a discrete M\u0026A, financing, or governance event, this clinical milestone is material to investors assessing the company's pipeline development and commercial prospects, particularly given Alpha Tau's dependence on Alpha DaRT success and the company's limited operating history.","classifier_version":"claude-haiku-4-5-20251001+prompt-6be895f9","taxonomy_version":"v1.3","classified_at":"2026-07-15T12:31:37.955871+00:00","company_name":"Alpha Tau Medical Ltd.","ticker":"DRTSW","filing_date":"2026-07-15"}]}